%0 Journal Article
%T CRISPR-based genetic screens advance cancer immunology.
%A Cao Y
%A Li X
%A Pan Y
%A Wang H
%A Yang S
%A Hong L
%A Ye L
%J Sci China Life Sci
%V 0
%N 0
%D 2024 Jul 23
%M 39048715
%F 10.372
%R 10.1007/s11427-023-2571-0
%X CRISPR technologies have revolutionized research areas ranging from fundamental science to translational medicine. CRISPR-based genetic screens offer a powerful platform for unbiased screening in various fields, such as cancer immunology. Immune checkpoint blockade (ICB) therapy has been shown to strongly affect cancer treatment. However, the currently available ICBs are limited and do not work in all cancer patients. Pooled CRISPR screens enable the identification of previously unknown immune regulators that can regulate T-cell activation, cytotoxicity, persistence, infiltration into tumors, cytokine secretion, memory formation, T-cell metabolism, and CD4+ T-cell differentiation. These novel targets can be developed as new immunotherapies or used with the current ICBs as new combination therapies that may yield synergistic efficacy. Here, we review the progress made in the development of CRISPR technologies, particularly technological advances in CRISPR screens and their application in novel target identification for immunotherapy.